New Market Trends in Biotech, Entertainment, and Organic Food



Wall Street Analyzer CEO Interview Series

NEW YORK, NY–(Marketwired – March 05, 2015) – RedHill Biopharma (NASDAQ: RDHL) (TASE: RDHL) CEO Dror Ben Asher discussed the company’s recent fourth quarter and year-end results which include a strong cash position of over $34 million, following the completion of a $14.4 million public offering last month. He also went over the 3 Phase III studies, currently running in parallel in the U.S., with 3 of the company’s leading gastrointestinal drugs: RHB-104 for Crohn’s disease, RHB-105 for treatment of H. pylori infection and BEKINDA™ for gastroenteritis and gastritis, noting that top-line data is expected from the RHB-105 and BEKINDA™ studies in Q2/2015 and Q4/2015 respectively. Mr. Ben Asher also stated that RedHill has filed marketing applications for 2 of its drugs, RIZAPORT™ for migraines (in the U.S. and Europe) and BEKINDA™ for oncology support (in Europe), and that the company has licensed in 2014 to Salix Pharmaceuticals the rights to its RHB-106 bowel preparation capsule.


Latitude 360 (OTCQX: LATX) CEO Brent Brown spoke about the company’s recent mega entertainment center opening at Crossgates in Guilderland, New York and an expansion planned for the greater New York City area involving four properties in Brooklyn, Jersey City, Lower Manhattan, and Times Square. He discussed a recent partnership with Brand Synergy Group which he feels will revolutionize restaurant entertainment by providing customers with an innovative entertainment experience, along with concierge service to help customers plan a party or event. Mr. Brown discussed LATX’s two main competitive advantages, their groundbreaking restaurant platform and their membership program, adding that the company is in a unique position to attract new members by offering them a comprehensive entertainment and dining experience.


Green PolkaDot Holdings (OTC: GPDB) CEO Rod Smith discussed current U.S. marketplace trends in the online wholesale of organic and non-GMO foods. He also went over the company’s preparations to launch a Health Merchant program for the purpose of improving their marketing capabilities. He stated that this program will be effective in converting first-time customers to long-term buyers by establishing relationships with merchants the consumer already knows and trusts. Mr. Smith then commented on GPDB’s agreement with LinkTrust, which was established through their affiliate program and will educate consumers on clean eating. He discussed GPDB’s sales goals for the next year, which include establishing a minimum of 5,000 merchants, each doing a minimum of $1000 in sales.


About WSA: 

The Wall Street Analyzer’s aim is to provide investors with the tools they need to make informed decisions on holding stocks. Our staff includes a mix of financial professionals and media savvy individuals whose experiences bring the best talent from both ends of the spectrum. On one hand our financial experience gives us the ability to identify promising, off the grid companies before the rest of the market uncovers them, and on the other hand our media experience allows us to produce interviews, which appeal to a larger audience. We provide a format in which more individual investors can understand a featured companies’ upside. Our philosophy is to turn stock tickers into stories, ideas into headlines, and technical and financial data into easier to understand data. Visit:

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by phrases such as SLWF or its management “believes,” “expects,” “anticipates,” “foresees,” “forecasts,” “estimates” or other words or phrases of similar import. Similarly, such statements in this release that describe the company’s business strategy, outlook, objectives, plans, intentions, or goals also are forward-looking statements. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements. These risks and uncertainties include, among other things, product price volatility, product demand, market competition, and risk inherent in the operations of a company. We assume no obligation to update any written or oral forward-looking statement made by us or on our behalf as a result of new information, future events or other factors.


RedHill Biopharma
Lauren Kwiecinski
Vice President (IR)
The Trout Group
Email contact

Latitude 360
Neil Steinberg
5W Public Relations
Email contact

Green PolkaDot Holdings
Rod Smith
(801) 787-8835
Email contact

BY, OTC Disclosure & News Service


Leave a Reply


Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.